Rivaxo 15gm Tablet

400.00


Pack Size:                 10’s


Composition :        Rivaroxaban


Pharmaceutical form :  tablet


Brand Name: GETZ


 

Description

Rivaxo 15gm Tablet

Rivaxo 15gm Tablet (Rivaroxaban) is a highly selective direct Factor Xa inhibitor with oral bioavailability. Rivaxo 15gm Tablet is chemically designated as 5-Chloro-N- ({(5S)-2-oxo-3- [4-(3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl) -2-thiophene-carboxamide.Rivaxo 15gm Tablet molecular formula is C19H18ClN3O5S. Hemorrhagic risk As with other anticoagulants, patients taking rivaroxaban are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of hemorrhage. Rivaxo 15gm Tablet administration should be discontinued if severe hemorrhage occurs. Renal impairment Rivaxo 15gm Tabletis to be used with caution in patients with creatinine clearance 15 – 29 ml/min. Use is not recommended in patients with creatinine clearance.Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial FibrillationRivaxo 15gm Tablet (Rivaroxaban) is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.


Uses

Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation Rivaxo (Rivaroxaban) is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. • Treatment of Deep Vein Thrombosis Rivaxo ) is indicated for the treatment of deep vein thrombosis (DVT). • Treatment of Pulmonary Embolism Rivaxo (Rivaroxaban) is indicated for the treatment of pulmonary embolism (PE).

Side effect :

Anemia (incl. respective laboratory parameters), dizziness, headache, eye hemorrhage (incl. conjunctival hemorrhage), hypotension, hematoma, epistaxis, hemoptysis, gingival bleeding, gastrointestinal tract hemorrhage (incl. rectal hemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipation, diarrhea, vomiting, pruritus

When not use :

Hypersensitivity to rivaroxaban or to any of the excipient of product. • Active clinically significant bleeding. • Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury,  ophthalmic surgery, recent intracranial hemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities

Reviews

There are no reviews yet.

Be the first to review “Rivaxo 15gm Tablet”

Your email address will not be published. Required fields are marked *

0